CAR T Cell Therapy: A New Era for Cancer Treatment (Review)

Purpose: Cancer is a leading cause of mortality worldwide, and conventional treatments and cytotoxic immunotherapies have limitations. Because tumors are complex and involve multiple genetic and cellular factors in tumorigenesis and metastasis, there is a need for an immunotherapy that targets tumors at both cellular and genetic levels. CAR T cell therapy has emerged as a novel T cell engineering practice, and this review synthesizes its advantages, advances, and differences from chemotherapy and radiotherapy. ---

Hypothesis: The review’s underlying claim is: if patient T cells are engineered to express chimeric antigen receptors that target tumor antigens in a major histocompatibility complex (MHC)-independent manner, then they can effectively eradicate hematologic cancers and potentially solid tumors. Advanced CAR designs, gene-editing tools, and nanoparticle delivery may further improve efficacy and safety. ---

Aims: - Present insight into the advantages and advances of CAR immunotherapy. - Describe the architectural ideology of T cell engineering and CAR design across generations. - Discuss modes of delivery, including viral and non-viral approaches. - Review challenges, advanced CAR features, clinical trials, success rates of approved therapies, and future prospects. ---

Delivery system: CAR T cell platform: - Patient T cells are isolated by leukapheresis, genetically engineered to express CARs, expanded in vitro, and reinfused. - CAR structure: extracellular antigen-binding domain (scFv from monoclonal antibody), hinge, transmembrane domain, and intracellular signaling domains. CAR generations: - First generation: CD3ζ signaling chain only. - Second generation: CD3ζ + one costimulatory domain (CD28 or 4-1BB/CD137). - Third generation: CD3ζ + two costimulatory domains (e.g., CD3ζ-CD28-OX40 or CD3ζ-CD28-4-1BB). - Fourth generation: Inducible expression of transgenic immune modifiers such as IL-12 (TRUCKs). Advanced CAR designs: - Bispecific CAR (e.g., CD19/CD20) - Tandem CAR (Tan-CAR) - Inhibitory CAR (I-CAR; PD-1/CTLA-4 domains) - Physiological CAR (receptor–ligand CAR) - Universal CAR (uCAR; biotin/FITC-labeled mAb recognition) - NK-CAR - CRISPR-CAR (e.g., CAR knock-in at TRAC locus) Gene delivery modes: - Viral vectors: γ-retrovirus, lentivirus, adenovirus. - Non-viral: transposon transfection (piggyBac, Sleeping Beauty), electroporation, nanoparticles. - Nanoparticles: polymeric nanocarriers delivering CAR genes to T cells; magnetic nanoparticles (Fe₃O₄) with cell-penetrating peptides. Payloads: CAR gene DNA, plasmid DNA, CRISPR/Cas9 components, mRNA-encoded CARs. ---

Approach: Review of preclinical and clinical literature. Model systems include: - In vitro: T cell isolation, transduction, expansion, and functional assays. - In vivo: Mouse tumor models, including leukemia, lymphoma, glioma, ovarian cancer, and solid tumor models. - Clinical: Phase I/II/III trials in hematologic malignancies (ALL, CLL, NHL, large B cell lymphoma) and solid tumors (glioblastoma, ovarian, pancreatic, breast, lung, prostate, neuroblastoma, etc.). - Approved therapies: Tisagenlecleucel (Kymriah) and axicabtagene ciloleucel (Yescarta). - Disease context: Cancer immunotherapy, with comparison to chemotherapy, radiotherapy, and stem cell transplantation. ---

Key methods: Techniques and endpoints highlighted across cited studies: - Leukapheresis and T cell isolation - Viral and non-viral gene transfer - CAR T cell expansion and persistence - Clinical response assessment: complete response (CR), overall response rate (ORR), minimal residual disease (MRD) - Survival analysis (3-month, 6-month, 8-month endpoints) - Toxicity monitoring: cytokine release syndrome (CRS), neurological toxicity, B cell aplasia, tumor lysis syndrome, anaphylaxis - CRISPR/Cas9 gene editing and multiplex genome editing - Nanoparticle-mediated gene delivery - Flow cytometry and cytokine assays (implied in clinical monitoring) ---

Key results: - CAR T cell therapy achieved remission rates of up to 80% in hematologic cancers, particularly ALL and non-Hodgkin lymphomas. - Second-generation anti-CD19 CARs achieved complete remission rates of up to 90% in patients with recurrent B-cell ALL. - ELIANA trial: tisagenlecleucel produced a 3-month complete remission rate of 83% and a 6-month survival rate of 89%. - ZUMA-1 trial: axicabtagene ciloleucel produced an 82% overall response rate and 54% complete remission rate after a single infusion in 8 months. - Blinatumomab (bispecific T cell engager): 26/36 (72%) patients under 15 years with relapsed/refractory ALL responded in 9 months. - Approved therapy costs: Yescarta $475,000; Kymriah $373,000; total cost with hospitalization and other drugs may reach ~$1,500,000 per patient. - CRISPR targeting of the TRAC locus increased T cell potency and produced consistent CAR expression; multiplex genome editing enabled universal donor cells. - Polymeric nanoparticles delivered CAR genes into T cell nuclei and recognized leukemia cells distinctly. ---

Interpretation: The authors claim that CAR T cell therapy is a “living drug” and a new era for cancer treatment. It has achieved durable remissions in hematologic malignancies, may substitute for transplant in some patients, and could offer a rapid, safer treatment regime. Advanced designs—bispecific CAR, Tan-CAR, I-CAR, CRISPR-CAR, NK-CAR, and nanoparticle delivery—may substantially improve anticancer effects and extend therapy to solid tumors. However, safety, cost-effectiveness, and quality challenges require further investigation. ---

Limitations: - Solid tumors remain difficult to treat because of phenotypic heterogeneity, antigen-negative cancer cells, and the immunosuppressive tumor microenvironment. - Serious side effects: cytokine release syndrome (CRS), neurological toxicity, B cell aplasia, tumor lysis syndrome, and anaphylaxis. - Antigen escape or loss can lead to tumor evasion. - Viral vector delivery carries risks of insertional mutagenesis and oncogene activation. - Electroporation has low transfection efficiency and can cause redundant cell damage. - Nanoparticle delivery is still largely preclinical. - Cost is extremely high, and manufacturing, transportation, and banking solutions remain challenging. - Long-term follow-up is needed to assess CAR T cell persistence and cytotoxicity. - Allogeneic and universal CAR T cell therapies require further clinical validation. - As a review, the article is not a systematic review or meta-analysis.